clinical trials

News

The SARCO41 study suggests Lilly's Verzenio could become the first targeted therapy for rare, aggressive tumour dedifferentiated liposarcoma.

News

Trials of AstraZeneca's anselamimab and Regeneron's Lynozyfic could deliver much-needed new therapeutic options for rare disease AL amyloidosis.

News

Millions of women with a breast cancer diagnosis could safely avoid chemotherapy that would not be effective, thanks to a genomics test.

News

Revolution Medicines' pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer.

News

Akeso and Summit's PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.

News

Lilly looks set to extend the reach of RET inhibitor Retevmo in RET+ lung cancer, as the LIBRETTO-432 trial shows its value as adjuvant therapy.